Vertex Pharmaceuticals is making headlines with a notable rebound in sales of its CRISPR-based therapy, Casgevy. This surge reflects the broader trends in the biopharmaceutical sector, where innovative treatments are increasingly gaining traction.
Casgevy’s Strong Performance
In the latest earnings report, Vertex revealed that sales of Casgevy, developed in collaboration with CRISPR Therapeutics, skyrocketed by more than 300% compared to the previous quarter. This impressive performance was a bright spot within Vertex’s overall financial results, leading to a 6% increase in its stock price shortly after the announcement.
Vertex recorded total revenues of $12 billion in 2025, with approximately $3.2 billion generated in the fourth quarter alone. This marks a 9% year-over-year increase, underscoring the company’s resilience in a competitive market.
Patient Adoption Increases
Casgevy, specifically targeting sickle cell disease and beta thalassemia, generated $54 million in sales during the fourth quarter. This figure exceeded analysts’ expectations and represented a significant increase from the $17 million reported in the previous quarter. The number of patients initiating the treatment process rose dramatically, from 109 in 2024 to 301 in 2025.
The treatment journey for Casgevy is lengthy, often taking nearly 12 months from the initial collection of a patient’s blood stem cells to the actual infusion. Vertex employs CRISPR gene editing technology to modify these cells to produce fetal hemoglobin. This alteration can alleviate the painful symptoms associated with these diseases, potentially offering a cure. However, the chemotherapy conditioning necessary for the procedure can deter some patients due to its severe side effects, including infertility.
Analysts Weigh In
According to Tyler Van Buren, a TD Cowen analyst, fluctuations in sales are likely as patients navigate the lengthy infusion schedule. The timing of treatments may also be influenced by personal factors, such as holiday schedules. He projected that Casgevy could generate around $227 million in sales for 2026, based on the current patient enrollment trends.
Vertex is optimistic about the future, with Chief Operating Officer Duncan McKechnie expressing confidence in the robust influx of patients expected to sustain the treatment’s growth.
Regulatory Developments
In a further boost to its prospects, Vertex received a priority voucher from the Food and Drug Administration (FDA). This designation will expedite the review process for Casgevy in younger patients aged 5 to 11. The company anticipates submitting a request for approval in the first half of 2026, which could significantly enhance revenue streams from this gene editing therapy.
Cystic Fibrosis Drug Contributions
Sales of Casgevy are part of a broader picture that includes a robust portfolio of cystic fibrosis treatments. Vertex’s revenues are predominantly derived from its cystic fibrosis medications, with over $10 billion of the total $12 billion earned in 2025 coming from products like Trikafta and Kaftrio. The company expects its cystic fibrosis franchise to remain a cornerstone of its financial success, bolstered by the growing acceptance of Casgevy and the introduction of a new non-opioid pain management medication, Journavx.
Looking Ahead
Vertex projects revenues for 2026 to be between $13 billion and $13.1 billion, including over $500 million anticipated from non-cystic fibrosis products. Investors are keenly watching upcoming data releases for the company’s experimental kidney drugs, povetacicept and inaxaplin. If approved, povetacicept, currently in late-stage trials for IgA nephropathy, is expected to generate substantial revenue, with estimates suggesting it could yield at least $1.2 billion annually.
Conclusion
Vertex Pharmaceuticals is charting a promising path with its CRISPR therapy, Casgevy, which is gaining momentum in the biopharmaceutical landscape. As the company continues to innovate and expand its treatment offerings, it stands poised to capitalize on significant revenue opportunities in the coming years.
- Casgevy sales increased by over 300% in Q4 2025.
- Vertex expects total revenues of $13 billion in 2026.
- The company received FDA priority review for Casgevy in younger patients.
- Upcoming data for kidney drugs may influence future growth.
- Cystic fibrosis treatments remain a major revenue driver for Vertex.
Read more → www.biopharmadive.com